{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00857:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00857%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003777,
    "timestamp_received": "2026-04-25T12:53:49.075228+00:00Z",
    "timestamp_returned": "2026-04-25T12:53:49.079005+00:00Z",
    "trace_id": "230325fc-364d-4ade-bf36-3ad8b4507fae"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00857:a",
      "indication": "Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.",
      "initial_approval_date": "2024-06-01",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab 200mg in combination with carboplatin (AUC 5) and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (AC 60/600) for reimbursement as a treatment option for the neoadjuvant treatment, and then pembrolizumab as a monotherapy treatment as an adjuvant treatment after surgery, of locally advanced or early stage triple negative breast cancer at high risk of recurrence in adult patients.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Triple-negative breast cancer",
      "raw_therapeutics": "Pembrolizumab (200mg), carboplatin AUC 5 and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (ac 60/600) therapy.",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00857",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2025, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6450/857_v3_Pembro_Carbo_5_Pacli_80_AC60_600.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6450/857_v3_Pembro_Carbo_5_Pacli_80_AC60_600.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2024-06-04",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}